1404480-15-4

Usage

Chemical compound

2-amino-benzooxazole-5-boronic acid hydrochloride

Structure

Contains a benzooxazole ring with an amino group and a boronic acid group attached to it.

Form

Hydrochloride salt

Usage

Commonly used in organic chemistry as a reagent for synthesizing various organic molecules.

Boronic Acid Group

Makes it valuable for synthesizing complex organic molecules, facilitating the formation of carbon-carbon and carbon-heteroatom bonds.

Stability

The hydrochloride salt form enhances stability and ease of handling in laboratory settings.

Upstream product

• 1224844-66-9 5-( 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2-amine 
• 7647-01-0 hydrogenchloride 
• 73183-34-3 bis(pinacol)diborane 
• 64037-07-6 5-bromo-1,3-benzoxazol-2-amine 
• 1404480-03-0 C₇H₇BrN₂OS 
• 7693-52-9 4-bromo-2-nitrophenol 
• 106-41-2 4-bromo-phenol 
• 40925-68-6 2-amino-4-bromo-phenol 

Downstream Products

• 1268454-23-4 (6-(2-aminobenzo[d]oxazol-5-yl)imidazo[1,2-a]pyridin-3-yl)(morpholino)methanone 
• 1224844-38-5 INK128 

Relevant academic research and scientific papers

Pyrazole compound and preparation and application methods thereof

The invention provides a pyrazole compound and preparation and application methods thereof. The pyrazole compound is synthesized by introducing 2-amido-benzoxazole groups into pyrazole. The prepared pyrazole compound is low in toxic and side effects, high in oral bioavailability, significant in inhibition on tumor cells such as human breast cancer cells, human lung cancer cells, human prostatic cancer cells, human gastric cancer cells and human malignant glioma cells and capable of providing new possibilities for developing high-efficiency and low-toxicity anti-tumor drugs. Meanwhile, the pyrazole compound is wide in material sources, simple in synthesizing processes and applicable to industrial production.

Enhanced treatment regimens using mTor inhibitors

The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV

The invention relates to an administration unit comprising a compound of formula and/or pharmaceutically acceptable salts thereof, and to a packaging comprising the administration unit according to the invention.

COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.

KINASE INHIBITOR POLYMORPHS

Polymorphs, hydrates, and solvates of chemical compounds that modulate kinase activity, including mTOR activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mTOR activity, are described herein.

KINASE INHIBITOR POLYMORPHS

Polymorphs of chemical compounds that modulate kinase activity, including PI3K activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3K activity, are described herein.

BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.